Merck (NYSE: MRK) announced topline results from the KEYNOTE-010 study of KEYTRUDA® (pembrolizumab) in advanced non-small-cell lung cancer (NSCLC) demonstrating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Leerink Partners Reiterates Market Perform on Merck (MRK) Following 3Q EPS Beat October 28, 2015 9:31 AM Leerink Affirms Merck (MRK) at 'Market Perform'; Additional KEYTRUDA Data Still NeededOctober 26, 2015 2:29 PM Merck’s KEYTRUDA® (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1October 26, 2015 9:01 AM Merck and the National Sleep Foundation Urge Insomnia Sufferers to Prioritize Sleep and Move Beyond TiredOctober 26, 2015 8:01 AM